Mayo Clinic researchers have developed a promising gene-editing therapy that directly corrects a genetic mutation responsible for autosomal dominant polycystic kidney disease (ADPKD), the most common ...

Western Midstream delivers robust operational performance, driving double-digit returns and a near 9% distribution yield. See why WES stock is a Buy.

Times of India’s Edit Page team comprises senior journalists with wide-ranging interests who debate and opine on the news and issues of the day. Trump’s geopolitics: His fans, mostly from the broad ...

Chris is a writer and editor with over 10 years of experience covering games and has a bachelor's degree in History from the University of Central Lancashire. He's mainly focused on guides, but has ...

MLPs differ from regular stocks in that interests in them are referred to as units, and the unitholders (not shareholders) are partners in the business. Importantly, these hybrid entities bring ...

This repository contains the official evaluation implementation of IF-Bench, the first high-quality benchmark for evaluating multimodal understanding of infrared images, and the training ...

A therapy that would once have been considered a feat of science fiction has reversed aggressive and incurable blood cancers in some patients, doctors report. The treatment involves precisely editing ...

Western Midstream Partners is a compelling distribution play with disciplined capital management and a growing asset base, especially in the Delaware Basin. WES recently agreed to acquire Aris Water ...

A group of Chinese scientists has overcome a challenge that stumped biologists for decades by developing a new gene-editing tool that can precisely manipulate millions of base pairs – the building ...

In May 2025, researchers announced that K.J. Muldoon, a baby boy born without the ability to process dietary protein properly, had become the first person to be treated with a customized gene-editing ...